Phase II Trial of Allogeneic Transplantation Plus Novel Drugs in Multiple Myeloma: Effect of Intensifying Reduced-Intensity Conditioning with Bortezomib and Adding Maintenance Treatment

Autor: Reinoso-Segura, Marta, Caballero-Velázquez, Teresa, Herrera, Pilar, Patriarca, Francesca, Fanin, Renato, Bruno, Benedetto, Einsele, Hermann, Nahi, Hareth, Granell, Miquel, López-Corral, Lucía, Reguera, Juan L., García-Cadenas, Irene, Gahrton, Gösta, Pérez-Simón, José A.
Zdroj: Transplantation and Cellular Therapy; 20220101, Issue: Preprints
Abstrakt: •Allogeneic stem cell transplantation is a curative option for high-risk multiple myeloma.•Combination therapies with new drugs could improve outcome after transplantation.•Intensifying conditioning with bortezomib is associated with a high response rate.•Maintenance therapy with bortezomib and lenalidomide decreases the risk of relapse after transplantation.
Databáze: Supplemental Index
Externí odkaz: